Russell Investments Group Ltd. Has $1.12 Million Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Russell Investments Group Ltd. boosted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Rating) by 71.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 53,205 shares of the company’s stock after purchasing an additional 22,209 shares during the period. Russell Investments Group Ltd. owned about 0.08% of Travere Therapeutics worth $1,119,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Armistice Capital LLC boosted its stake in Travere Therapeutics by 9.7% in the third quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock valued at $143,799,000 after buying an additional 516,000 shares in the last quarter. Sofinnova Investments Inc. grew its stake in shares of Travere Therapeutics by 85.6% during the third quarter. Sofinnova Investments Inc. now owns 394,678 shares of the company’s stock worth $9,725,000 after buying an additional 182,085 shares during the last quarter. Ensign Peak Advisors Inc increased its holdings in shares of Travere Therapeutics by 26.6% during the third quarter. Ensign Peak Advisors Inc now owns 97,330 shares of the company’s stock worth $2,398,000 after buying an additional 20,431 shares in the last quarter. AlphaCentric Advisors LLC bought a new position in shares of Travere Therapeutics in the 4th quarter valued at $392,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Travere Therapeutics by 25.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,432 shares of the company’s stock valued at $198,000 after acquiring an additional 1,928 shares in the last quarter.

Travere Therapeutics Price Performance

TVTX opened at $16.31 on Friday. The firm’s fifty day moving average price is $19.49 and its two-hundred day moving average price is $20.28. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -3.67 and a beta of 0.46. The company has a debt-to-equity ratio of 1.99, a current ratio of 4.63 and a quick ratio of 4.58. Travere Therapeutics, Inc. has a 1 year low of $14.51 and a 1 year high of $29.14.

Travere Therapeutics (NASDAQ:TVTX – Get Rating) last issued its quarterly earnings data on Thursday, February 23rd. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.01. Travere Therapeutics had a negative net margin of 130.98% and a negative return on equity of 236.09%. The business had revenue of $55.87 million during the quarter, compared to the consensus estimate of $54.80 million. As a group, analysts anticipate that Travere Therapeutics, Inc. will post -4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TVTX has been the topic of several recent research reports. Guggenheim cut their target price on shares of Travere Therapeutics from $40.00 to $23.00 in a research report on Tuesday, May 2nd. Bryan, Garnier & Co raised Travere Therapeutics from a “sell” rating to a “neutral” rating in a research note on Friday, May 5th. Piper Sandler decreased their price objective on shares of Travere Therapeutics from $44.00 to $41.00 in a research report on Monday, March 13th. Canaccord Genuity Group dropped their target price on shares of Travere Therapeutics from $44.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, February 28th. Finally, Barclays lowered their price objective on Travere Therapeutics from $37.00 to $31.00 and set an “overweight” rating for the company in a research report on Tuesday, February 21st. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $29.85.

Travere Therapeutics Company Profile

(Get Rating)

Travere Therapeutics, Inc is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm’s products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.